Online citations, reference lists, and bibliographies.
← Back to Search

Reduction Of N(ω)-hydroxy-L-arginine By The Mitochondrial Amidoxime Reducing Component (mARC).

J. Kotthaus, B. Wahl, Antje Havemeyer, Joscha Kotthaus, Dennis Schade, D. Garbe-Schönberg, R. Mendel, F. Bittner, B. Clement
Published 2011 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
NOSs (nitric oxide synthases) catalyse the oxidation of L-arginine to L-citrulline and nitric oxide via the intermediate NOHA (N(ω)-hydroxy-L-arginine). This intermediate is rapidly converted further, but to a small extent can also be liberated from the active site of NOSs and act as a transportable precursor of nitric oxide or potent physiological inhibitor of arginases. Thus its formation is of enormous importance for the nitric-oxide-generating system. It has also been shown that NOHA is reduced by microsomes and mitochondria to L-arginine. In the present study, we show for the first time that both human isoforms of the newly identified mARC (mitochondrial amidoxime reducing component) enhance the rate of reduction of NOHA, in the presence of NADH cytochrome b₅ reductase and cytochrome b₅, by more than 500-fold. Consequently, these results provide the first hints that mARC might be involved in mitochondrial NOHA reduction and could be of physiological significance in affecting endogenous nitric oxide levels. Possibly, this reduction represents another regulative mechanism in the complex regulation of nitric oxide biosynthesis, considering a mitochondrial NOS has been identified. Moreover, this reduction is not restricted to NOHA since the analogous arginase inhibitor NHAM (N(ω)-hydroxy-N(δ)-methyl-L-arginine) is also reduced by this system.
This paper references
10.1016/0006-291X(92)91279-Y
Cytochrome P450 catalyzes the oxidation of N omega-hydroxy-L-arginine by NADPH and O2 to nitric oxide and citrulline.
J. L. Boucher (1992)
10.1006/ABBI.1994.1232
Purification and characterization of the constitutive nitric oxide synthase from human placenta.
E. Garvey (1994)
Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney.
T. Ogawa (1989)
10.1016/S0005-2736(96)00240-4
Phospholipid composition of highly purified mitochondrial outer membranes of rat liver and Neurospora crassa. Is cardiolipin present in the mitochondrial outer membrane?
A. D. de Kroon (1997)
10.1074/JBC.271.24.14631
Endothelial Nitric-oxide Synthase
P. Chen (1996)
N omega-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from L-arginine.
D. Stuehr (1991)
10.1016/S0304-3835(99)00119-6
Detoxification of carcinogenic aromatic and heterocyclic amines by enzymatic reduction of the N-hydroxy derivative.
R. King (1999)
10.1094/MPMI.2001.14.10.1189
The antioxidants of legume nodule mitochondria.
I. Iturbe-Ormaetxe (2001)
10.1021/jo702150d
Synthetic approaches to N(delta)-methylated L-arginine, N(omega)-hydroxy-L-arginine, L-citrulline, and N(delta)-cyano-L-ornithine.
D. Schade (2008)
High-performance liquid chromatographic determination of nitric oxide synthase-related arginine derivatives in vitro and in vivo.
J. Meyer (1997)
10.1016/J.TIPS.2005.02.005
Mitochondrial nitric oxide synthase.
P. Ghafourifar (2007)
Simultaneous determination of 37 trace elements in 28 international rock standards by ICP-MS
C. D. Garbe-Schönberg (1993)
10.1074/jbc.M603606200
Evidence for the Pathophysiological Role of Endogenous Methylarginines in Regulation of Endothelial NO Production and Vascular Function*
A. Cardounel (2007)
10.1074/jbc.M607697200
Identification of the Missing Component in the Mitochondrial Benzamidoxime Prodrug-converting System as a Novel Molybdenum Enzyme*
Antje Havemeyer (2006)
10.1111/j.1365-2958.1996.tb02525.x
Involvement of the narJ and mob gene products in distinct steps in the biosynthesis of the molybdoenzyme nitrate reductase in Escherichia coli
T. Palmer (1996)
10.1016/S0008-6363(99)00162-5
Biological significance of endogenous methylarginines that inhibit nitric oxide synthases.
J. Leiper (1999)
10.1080/00211919208050834
Bestimmung stabiler Molybdän-Isotope in biologischem Material mit Hilfe der “Inductively coupled plasma mass spectrometry”
M. A. Soltani-neshan (1992)
10.1074/jbc.M304940200
Proteomic Analysis of the Mouse Liver Mitochondrial Inner Membrane*
S. Da Cruz (2003)
10.1016/S0076-6879(78)52011-9
[9] Detergent-solubilized NADH-cytochrome b5 reductase
K. Mihara (1978)
10.1016/S0946-672X(01)80065-1
Molybdenum metabolism: stable isotope studies in infancy.
E. Sievers (2001)
10.1002/cbic.200500527
How to Control NO Production in Cells: Nω,Nω‐Dimethyl‐L‐Arginine Dimethylaminohydrolase as a Novel Drug Target
M. Knipp (2006)
10.1021/jm8010417
The fourth molybdenum containing enzyme mARC: cloning and involvement in the activation of N-hydroxylated prodrugs.
S. Grünewald (2008)
10.1021/BI00269A004
Human serum thymidine triphosphate nucleotidohydrolase: purification and properties of a new enzyme.
N. Dahlmann (1982)
The pterin component of the molybdenum cofactor. Structural characterization of two fluorescent derivatives.
J. L. Johnson (1984)
10.1016/0014-2999(95)00046-N
Increase in serum NG-hydroxy-L-arginine in rats treated with bacterial lipopolysaccharide.
M. Hecker (1995)
10.1006/BBRC.1993.1380
Particular ability of liver P450s3A to catalyze the oxidation of N omega-hydroxyarginine to citrulline and nitrogen oxides and occurrence in no synthases of a sequence very similar to the heme-binding sequence in P450s.
J. P. Renaud (1993)
10.1016/j.bmc.2008.10.058
Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads.
J. Kotthaus (2008)
10.1124/JPET.104.072389
NADH Cytochrome b5 Reductase and Cytochrome b5 Catalyze the Microsomal Reduction of Xenobiotic Hydroxylamines and Amidoximes in Humans
J. R. Kurian (2004)
10.1016/S1357-2725(96)00089-1
Possible mechanism of nitric oxide production from N(G)-hydroxy-L-arginine or hydroxylamine by superoxide ion.
P. Vetrovsky (1996)
10.1111/j.1440-1681.2007.04638.x
ARGINASE: A CRITICAL REGULATOR OF NITRIC OXIDE SYNTHESIS AND VASCULAR FUNCTION
W. Durante (2007)
10.1016/0003-9861(69)90300-2
The hydroxylamine reductase of mitochondria.
M. Bernheim (1969)
10.1016/0005-2736(90)90036-N
Improved methods to isolate and subfractionate rat liver mitochondria. Lipid composition of the inner and outer membrane.
R. Hovius (1990)
10.1056/NEJM199312303292706
The L-arginine-nitric oxide pathway.
S. Moncada (1993)
10.1113/jphysiol.2006.108993
l‐Arginine supplementation or arginase inhibition augments reflex cutaneous vasodilatation in aged human skin
Lacy A. Holowatz (2006)
10.1038/227680A0
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
U. Laemmli (1970)
10.1016/J.BMC.2007.11.066
Nδ-Methylated l-arginine derivatives and their effects on the nitric oxide generating system
J. Kotthaus (2008)
10.1042/BST025383SC
NITRIC OXIDE PHYSIOLOGY
S. Moncada (1997)
Oxidation and reduction of nitrogen via CYP450: importance of the reduction of genotoxic N-hydroxylated functional groups. In Drug Metabolism: Towards the Next Millenium (Gooderham
B. Clement (1998)
10.1007/s000180050352
Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization
J. L. Boucher (1999)
10.1006/BBRC.1994.1909
Inhibition of rat liver arginase by an intermediate in NO biosynthesis, NG-hydroxy-L-arginine: implications for the regulation of nitric oxide biosynthesis by arginase.
F. Daghigh (1994)
dimethylaminohydrolase, from rat kidney
N-dimethylarginine (1997)
10.1073/PNAS.79.22.6856
Structural and metabolic relationship between the molybdenum cofactor and urothione.
J. L. Johnson (1982)
10.2174/187152707781387233
Nitric oxide in migraine.
L. Neeb (2007)
Detergent-solubilized NADH-cytochrome b5 reductase.
K. Mihara (1978)
10.1007/978-1-4613-1607-7
Pathophysiology and Pharmacology of Heart Disease
I. Anand (1989)
10.1016/J.BBRC.2006.08.123
Reduction of Nω-hydroxy-l-arginine to l-arginine by pig liver microsomes, mitochondria, and human liver microsomes
B. Clement (2006)
Oxidation and reduction of nitrogen via CYP 450 : importance of the reduction of genotoxic N - hydroxylated functional groups
B. Clement (1998)
10.1016/j.pharmthera.2010.02.005
Modulating the NO generating system from a medicinal chemistry perspective: current trends and therapeutic options in cardiovascular disease.
D. Schade (2010)
Nitric oxide: physiology, pathophysiology, and pharmacology.
S. Moncada (1991)
10.1007/BF02974016
Nitric oxide synthase from bovine pancreas: Purification and characterization
Soo Wan Nam (1998)
10.1042/BJ0540437
A new method for preparing flavin-adenine dinucleotide.
L. Whitby (1953)
10.1006/ABIO.1997.2008
High-Performance Liquid Chromatographic Determination of Nitric Oxide Synthase-Related Arginine Derivativesin Vitroandin Vivo☆
J. Meyer (1997)
10.1111/J.1751-908X.1993.TB00122.X
SIMULTANEOUS DETERMINATION OF THIRTY‐SEVEN TRACE ELEMENTS IN TWENTY‐EIGHT INTERNATIONAL ROCK STANDARDS BY ICP‐MS
C. Garbe-Schoenberg (1993)
10.1007/s00395-003-0454-3
Nitric oxide synthase activity in rat cardiac mitochondria
B. Zanella (2003)
NADH cytochrome
J. R. Kurian (2004)
10.1124/dmd.105.005249
HEPATIC, EXTRAHEPATIC, MICROSOMAL, AND MITOCHONDRIAL ACTIVATION OF THE N-HYDROXYLATED PRODRUGS BENZAMIDOXIME, GUANOXABENZ, AND RO 48-3656 ([[1-[(2S)-2-[[4-[(HYDROXYAMINO)IMINOMETHYL]BENZOYL]AMINO]-1-OXOPROPYL]-4-PIPERIDINYL]OXY]-ACETIC ACID)
B. Clement (2005)
Reduction of Nomega-hydroxy-L-arginine to L-arginine by pig liver microsomes, mitochondria, and human liver microsomes.
B. Clement (2006)



This paper is referenced by
10.1016/J.CCR.2011.02.016
Comparative Genomics and Evolution of Molybdenum Utilization.
Y. Zhang (2011)
10.1021/tx500174u
Reduction of sulfamethoxazole hydroxylamine (SMX-HA) by the mitochondrial amidoxime reducing component (mARC).
Gudrun Ott (2014)
Reduktion N-oxygenierter Verbindungen durch die mitochondriale Amidoxim Reduzierende Komponente (mARC)
Danilo Froriep (2013)
10.1016/j.bmc.2011.01.066
Synthesis and biological evaluation of L-valine-amidoximeesters as double prodrugs of amidines.
Joscha Kotthaus (2011)
10.3109/00498254.2013.767481
Activation of the anti-cancer agent upamostat by the mARC enzyme system
Danilo Froriep (2013)
10.1128/EC.05096-11
The Chlamydomonas reinhardtii Molybdenum Cofactor Enzyme crARC Has a Zn-Dependent Activity and Protein Partners Similar to Those of Its Human Homologue
Alejandro Chamizo-Ampudia (2011)
10.1074/jbc.M112.419424
The Mitochondrial Amidoxime-reducing Component (mARC1) Is a Novel Signal-anchored Protein of the Outer Mitochondrial Membrane*
Julian M Klein (2012)
10.1021/bi2005762
Structural studies of the molybdenum center of mitochondrial amidoxime reducing component (mARC) by pulsed EPR spectroscopy and 17O-labeling.
Asha Rajapakshe (2011)
10.1074/jbc.M115.640052
The Pivotal Role of the Mitochondrial Amidoxime Reducing Component 2 in Protecting Human Cells against Apoptotic Effects of the Base Analog N6-Hydroxylaminopurine*
B. Plitzko (2015)
10.7282/T32V2K95
Studies on the influence of folic acid and riboflavin on nitric oxide production in cultured murine macrophage cells
Marijke Rittmann (2018)
10.1038/s41388-020-01417-6
A novel mitochondrial amidoxime reducing component 2 is a favorable indicator of cancer and suppresses the progression of hepatocellular carcinoma by regulating the expression of p27
Dehai Wu (2020)
10.1038/s41598-020-58859-x
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling
A. Romano (2020)
10.1039/c2dt32376a
The molybdenum oxotransferases and related enzymes.
R. Hille (2013)
10.3390/ijms18030670
Study of Different Variants of Mo Enzyme crARC and the Interaction with Its Partners crCytb5-R and crCytb5-1
Alejandro Chamizo-Ampudia (2017)
10.1016/j.tox.2014.07.007
Mitochondrial proteomic analysis reveals the molecular mechanisms underlying reproductive toxicity of zearalenone in MLTC-1 cells.
Yuzhe Li (2014)
10.1074/jbc.RA119.007606
Mitochondrial amidoxime-reducing component 2 (MARC2) has a significant role in N-reductive activity and energy metabolism
Sophia Rixen (2019)
10.3109/03602532.2011.608682
The fourth mammalian molybdenum enzyme mARC: current state of research
Antje Havemeyer (2011)
10.1124/dmd.116.071845
Defining the Role of the NADH–Cytochrome-b5 Reductase 3 in the Mitochondrial Amidoxime Reducing Component Enzyme System
B. Plitzko (2016)
10.3390/molecules23123287
From the Eukaryotic Molybdenum Cofactor Biosynthesis to the Moonlighting Enzyme mARC
Manuel Tejada-Jiménez (2018)
10.1074/jbc.M113.474916
The Involvement of Mitochondrial Amidoxime Reducing Components 1 and 2 and Mitochondrial Cytochrome b5 in N-Reductive Metabolism in Human Cells*
B. Plitzko (2013)
10.1371/journal.pone.0105371
The N-Reductive System Composed of Mitochondrial Amidoxime Reducing Component (mARC), Cytochrome b5 (CYB5B) and Cytochrome b5 Reductase (CYB5R) Is Regulated by Fasting and High Fat Diet in Mice
H. H. Jakobs (2014)
10.1007/s00775-014-1234-2
Nitrite reduction by molybdoenzymes: a new class of nitric oxide-forming nitrite reductases
L. Maia (2014)
10.1124/dmd.118.082453
The Involvement of the Mitochondrial Amidoxime Reducing Component (mARC) in the Reductive Metabolism of Hydroxamic Acids
Carsten Ginsel (2018)
10.1007/978-94-007-7500-8_13
Molybdenum in human health and disease.
G. Schwarz (2013)
10.1002/biof.1362
The molybdenum cofactor enzyme mARC: Moonlighting or promiscuous enzyme?
Ángel Llamas (2017)
Protein-Protein Interactions of Human Mitochondrial Amidoxime-Reducing Component in Mammalian Cells
J. Thomas (2016)
10.3389/fpls.2014.00028
Molybdenum metabolism in plants and crosstalk to iron
F. Bittner (2014)
10.1007/s00429-012-0472-8
Genomic transcriptional profiling in LOU/C/Jall rats identifies genes for successful aging
V. Paban (2012)
10.1007/978-94-007-5561-1_15
Metabolism of molybdenum.
R. Mendel (2013)
10.1021/jacs.5b01112
Oxyl and hydroxyl radical transfer in mitochondrial amidoxime reducing component-catalyzed nitrite reduction.
J. Yang (2015)
10.1016/j.bbamcr.2012.02.007
Cell biology of molybdenum in plants and humans.
R. Mendel (2012)
10.1039/c0ob01117g
Prodrug design for the potent cardiovascular agent Nω-hydroxy-L-arginine (NOHA): synthetic approaches and physicochemical characterization.
D. Schade (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar